botulinum toxin type A
Cold Chain RequiredFDA Approved
Description
Botulinum toxin type A is a neurotoxin that temporarily paralyzes muscles by blocking acetylcholine release at neuromuscular junctions. It is used off-label for facial myokymia and other movement disorders involving involuntary muscle contractions. The therapeutic effect typically lasts 3-6 months, requiring repeat injections.
Indications & Therapeutic Use
chronic migraine, cervical dystonia, blepharospasm, strabismus, facial myokymia, hyperhidrosis, overactive bladder
Global Availability (9 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Available Through
This drug is available for procurement through the following fulfilment partner.
Fulfilment Partner
botulinum toxin type A
| Generic Name | botulinum toxin type A |
| Brands | 1 brand available |
| Active Ingredient | onabotulinumtoxinA |
| Drug Class | chronic migraine |
| Manufacturer | Allergan (AbbVie) |
| Dosage Forms | powder for injection 50 units, 100 units, 200 units per vial |
| Medical Code | M03AX01 |
| Orphan Status | No |
| Cold Chain | Required |
| Lead Time | 14 days |
| Reg. Status | FDA Approved |
| Countries | 9 countries |
Authority Signals
Last Verified3/21/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations10 Validated Nodes